跳至主要内容
临床试验/CTRI/2018/05/013958
CTRI/2018/05/013958招募中未知

Effectiveness and Safety Profile of TNF alpha Inhibitors inRefractory Spondyloarthopathies: An Observational Study.

Department of Pharmacology Institute of Postgraduate Medical Education and Research Kolkata0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Adult patients of age between 18-60 years of either gender clinically diagnosed as cases of Ankylosing Spondylitis or Psoriatic arthritis who have been advised TNF alpha inhibitor (Infliximab or Adalimumab) therapy as per institutional treatment protocol.
  • 2. Patients who satisfy eligibility criteria for getting TNF alpha inhibitors.
  • 3. Subjects willing to give written informed consent and comply with study related instructions.

排除标准

  • 1. Patients of Ankylosing Spondylitis or Psoriatic arthritis having any clinical condition were TNF alpha inhibitor (Infliximab or Adalimumab) therapy is contraindicated.
  • 2. Subjects unwilling to give written informed consent and comply with study related instructions.

研究者

发起方
Department of Pharmacology Institute of Postgraduate Medical Education and Research Kolkata

相似试验

Effects and Safety of TNF alpha Inhibitors... | 临床试验